Crowded Waiting Rooms, Empty Pipelines: The Diseases Medicine Keeps Forgetting to Fund

The conventional story told about pharmaceutical neglect focuses on rarity — the child with a one-in-a-million enzyme deficiency, the adult with a mutation so uncommon it has no name in most clinical textbooks. That story is real, and it matters. But a quieter, less intuitive crisis runs alongside it: diseases affecting hundreds of thousands, sometimes millions, of Americans that nonetheless struggle to attract the capital, clinical attention, and commercial momentum necessary to move new treatments forward.

This is not a failure of scientific imagination. Researchers understand the biology of idiopathic pulmonary fibrosis well enough to know it is devastating, progressive, and largely untreatable beyond slowing its advance. Clinicians treating primary progressive multiple sclerosis have watched patients deteriorate for decades with almost no disease-modifying options. Psychiatrists managing treatment-resistant depression see patients cycle through approved medications without meaningful relief, year after year. The science is not absent. The patients are not absent. What is absent, with striking consistency, is the money.

The Blockbuster Gravity Well

To understand why large-population diseases sometimes go underfunded, it helps to understand how pharmaceutical investment actually works. Venture capital and large pharma alike are drawn toward two poles: blockbuster drugs for conditions with enormous, easily captured markets — think cardiovascular disease or type 2 diabetes — and rare diseases that qualify for orphan drug designation, with its accompanying tax credits, regulatory fast-tracking, and seven-year market exclusivity provisions.

What falls between those poles is a category that might be called the "middle neglect" — conditions that are neither small enough to qualify for orphan incentives nor commercially clean enough to attract blockbuster investment. These are diseases where the patient population is real and substantial, but where the path to return on investment is complicated by heterogeneous patient response, the absence of clear biomarkers, the difficulty of defining clinical endpoints that regulators will accept, or simply the fact that existing generic treatments, however inadequate, reduce the perceived urgency of innovation.

Idiopathic pulmonary fibrosis, which affects an estimated 100,000 Americans at any given time and carries a median survival of only two to five years after diagnosis, illustrates this trap. Two antifibrotic drugs have been approved, but neither halts disease progression — they slow it. The market exists, but the complexity of demonstrating meaningful improvement over existing therapies creates a high regulatory bar that discourages new entrants. Investment flows to the easier win.

When Prevalence Becomes a Liability

There is a counterintuitive dynamic at work in how the industry evaluates large patient populations. A disease affecting two million people might seem like a commercial goldmine, but if those two million patients respond inconsistently to treatment, require lengthy and expensive clinical trials to demonstrate efficacy, and lack the kind of dramatic, measurable outcomes that make for a compelling regulatory package, the financial calculus shifts quickly.

Treatment-resistant depression offers a particularly instructive case. Roughly one-third of the approximately 21 million American adults diagnosed with major depressive disorder each year do not respond adequately to first-line antidepressants. That is a population of staggering size. Yet for decades, the pipeline for genuinely novel mechanisms — not reformulations of existing monoamine-targeting drugs — remained thin. The reasons are structural: psychiatric trials are long, dropout rates are high, placebo response rates are notoriously variable, and the FDA's expectations for demonstrating efficacy in treatment-resistant populations are demanding.

The recent approval of esketamine represented a genuine breakthrough, and a handful of companies are now pursuing psychedelic-derived compounds and neuromodulation approaches. But the investment surge remains modest relative to the scale of need, and many of those efforts are concentrated in startups with limited runway rather than in the sustained, well-resourced programs the problem deserves.

Primary Progressive MS: A Disease That Waited Decades

Primary progressive multiple sclerosis, which accounts for roughly 15 percent of all MS diagnoses in the United States, spent the better part of three decades without a single approved therapy. While relapsing-remitting MS attracted intense commercial interest — and a robust pipeline of immunomodulatory drugs — the progressive form, which lacks the visible inflammatory episodes that relapsing disease presents, proved far harder to study and far less commercially appealing.

The 2017 approval of ocrelizumab for primary progressive MS was celebrated precisely because it ended such a long drought. But the underlying dynamic that created that drought has not disappeared. Progressive neurological diseases without clear inflammatory signatures remain difficult targets, and the investment community's appetite for them is shaped by the memory of how many attempts failed before one succeeded.

This history matters because it illustrates that neglect is not always a matter of indifference. Sometimes it reflects accumulated scar tissue from prior investment losses, creating a self-reinforcing cycle in which the absence of successful precedents discourages the attempts that might establish them.

What the Funding Gap Actually Costs

The human cost of this dynamic is not abstract. Patients with treatment-resistant depression lose years of functional life while waiting for options beyond electroconvulsive therapy and off-label prescribing. Patients with idiopathic pulmonary fibrosis are told that their disease will progress regardless of what medicine can currently offer. Patients with primary progressive MS watch their neurological function decline on a trajectory that approved therapies can influence only modestly.

The systemic cost is equally significant. When large patient populations go undertreated, the downstream burden falls on disability systems, emergency departments, and family caregivers — costs that are diffuse enough to be invisible in any single balance sheet but enormous in aggregate. A 2023 analysis published in a leading health economics journal estimated that the total economic burden of treatment-resistant depression in the United States exceeds $300 billion annually, a figure that dwarfs the investment flowing into novel mechanisms.

Structural Reforms and Emerging Responses

There are signals, however tentative, that the funding landscape is beginning to shift. The National Institutes of Health has expanded grant programs specifically targeting diseases with inadequate commercial pipelines. Patient advocacy organizations for conditions like pulmonary fibrosis and progressive MS have grown more sophisticated in their ability to fund early-stage research and engage with regulatory agencies to shape trial design standards.

Some biotechs are also beginning to apply genomic and biomarker-driven stratification strategies to these traditionally heterogeneous diseases — essentially using precision medicine tools to carve out more tractable, better-defined patient subpopulations within large, complex conditions. If a disease affecting two million patients can be stratified into a subgroup of 300,000 with a shared genetic signature and predictable treatment response, the regulatory and commercial math begins to change.

Gene therapy approaches, while still early, are being explored for some fibrotic and neurodegenerative conditions in ways that would have seemed speculative a decade ago. The question is whether those efforts will receive the sustained investment necessary to reach patients, or whether they will stall in the same funding desert that has claimed so many prior attempts.

The Obligation Beyond the Balance Sheet

Biotech's capacity for innovation is genuine and well-documented. The same industry that engineered mRNA vaccines in under a year and developed gene therapies capable of correcting single-gene disorders with a single infusion is, by any measure, one of the most scientifically productive enterprises in human history. That productivity makes the gaps more visible, not less.

The diseases described here are not scientifically intractable. They are financially inconvenient. That distinction matters because financial inconvenience is a problem with potential solutions — in regulatory incentive design, in public-private funding partnerships, in the way academic research institutions prioritize translational work. The patients filling those crowded waiting rooms are not waiting for a miracle. They are waiting for the industry to decide they are worth the effort.